ATE450622T1 - Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit - Google Patents

Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit

Info

Publication number
ATE450622T1
ATE450622T1 AT02777275T AT02777275T ATE450622T1 AT E450622 T1 ATE450622 T1 AT E450622T1 AT 02777275 T AT02777275 T AT 02777275T AT 02777275 T AT02777275 T AT 02777275T AT E450622 T1 ATE450622 T1 AT E450622T1
Authority
AT
Austria
Prior art keywords
genes
cardiovascular disease
prognosis
prediction
prevention
Prior art date
Application number
AT02777275T
Other languages
English (en)
Inventor
Marc Munnes
Mathias Gehrmann
Maresa Wick
Gerd Schmitz
Original Assignee
Siemens Healthcare Diagnostics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics filed Critical Siemens Healthcare Diagnostics
Application granted granted Critical
Publication of ATE450622T1 publication Critical patent/ATE450622T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT02777275T 2001-10-08 2002-10-02 Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit ATE450622T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124145.4A GB0124145D0 (en) 2001-10-08 2001-10-08 Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
PCT/EP2002/011034 WO2003031650A2 (en) 2001-10-08 2002-10-02 Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease

Publications (1)

Publication Number Publication Date
ATE450622T1 true ATE450622T1 (de) 2009-12-15

Family

ID=9923436

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02777275T ATE450622T1 (de) 2001-10-08 2002-10-02 Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit

Country Status (6)

Country Link
EP (1) EP1436425B1 (de)
AT (1) ATE450622T1 (de)
AU (1) AU2002338852A1 (de)
DE (1) DE60234619D1 (de)
GB (1) GB0124145D0 (de)
WO (1) WO2003031650A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1448600A4 (de) 2001-09-07 2004-12-22 Bristol Myers Squibb Co Für einen neuen menschlichen g-protein-gekoppelten rezeptor hgprbmy39 codierendes polynukleotid
AU2004268180A1 (en) * 2003-08-29 2005-03-10 Integragen Human obesity susceptibility gene and uses thereof
EP1522857A1 (de) 2003-10-09 2005-04-13 Universiteit Maastricht Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
WO2005095641A1 (en) * 2004-03-03 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 11 (map3k11)
EP2527837A1 (de) 2004-10-04 2012-11-28 University of Washington Verfahren zur Verhinderung von Zelltod oder -entzündung bei Säugetieren
US20110021433A1 (en) * 2004-10-04 2011-01-27 Harlan John M Methods for treating or preventing heart failure
US8648045B2 (en) 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
US8119601B2 (en) 2005-03-10 2012-02-21 Ben-Gurion University Of The Negev Research And Development Authority Ltd. Voltage dependent anion channel (VDAC1) compositions and methods of use thereof for regulating apoptosis
US8093369B2 (en) 2005-10-11 2012-01-10 Ben Gurion University Of The Negev Research And Development Authority Ltd. Compositions for silencing the expression of VDAC1 and uses thereof
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
US7550300B1 (en) * 2007-11-29 2009-06-23 Capgen Sciences, Inc. Prediction of bare metal stent restenosis
NZ586746A (en) * 2008-01-23 2012-07-27 Righospitalet Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
WO2010037181A1 (en) * 2008-10-03 2010-04-08 The Walter And Eliza Hall Institute Of Medical Research Cell therapy and compositions therefor
EA201270316A1 (ru) 2009-08-25 2012-09-28 БиДжи МЕДИСИН, ИНК. Галектин-3 и сердечная ресинхронизирующая терапия
US9758559B2 (en) 2013-07-25 2017-09-12 B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University Short peptides derived from VDAC1, compositions and methods of use thereof
CN108350048B (zh) 2015-08-07 2024-02-09 Alx肿瘤生物技术公司 具有SIRP-α结构域或其变体的构建体
EP3373939A4 (de) 2015-11-10 2019-06-26 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Mittel und verfahren zur verringerung der tumorigenität von krebsstammzellen
PL3658589T3 (pl) 2017-07-26 2024-03-18 Forty Seven, Inc. Przeciwciała anty-sirp-alfa i powiązane sposoby
BR112021024003A2 (pt) 2019-05-31 2022-04-19 Alx Oncology Inc Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033810T2 (de) * 1989-10-18 2002-03-28 Us Health Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper
GB0007268D0 (en) * 2000-03-24 2000-05-17 Cyclacel Ltd Cell cycle progression proteins

Also Published As

Publication number Publication date
AU2002338852A1 (en) 2003-04-22
DE60234619D1 (de) 2010-01-14
EP1436425A2 (de) 2004-07-14
GB0124145D0 (en) 2001-11-28
WO2003031650A3 (en) 2004-02-12
WO2003031650A2 (en) 2003-04-17
EP1436425B1 (de) 2009-12-02

Similar Documents

Publication Publication Date Title
ATE450622T1 (de) Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
EP1900827A3 (de) Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Verhinderung und Behandlung maligner Neoplasien
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
WO2005047534A3 (en) Methods and compositions for the response prediction of malig-nant neoplasia to treatment
EP2006298A3 (de) Jugendliches Hämochromatose-Gen (HFE2A), Expressionsprodukte und Verwendungen davon
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO2003013537A3 (en) Irinotecan for treatment of cancer
IL169367A0 (en) Defensin proteins
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2006037485A3 (en) Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
ATE367825T1 (de) Zusammensetzung und kit zur verwendung in der tumorbehandlung
WO2003027633A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
IL169256A0 (en) Metalloprotease proteins
WO2004111270A3 (en) Differential gene expression in schizophrenia
WO2002097127A3 (en) Genes and proteins for prevention, prediction, diagnosis, prognosis and treatment of chronic lung disease
ATE546548T1 (de) Verfahren zur prognose des nutzens einer antioxidationshemmenden therapie zur vorbeugung von herz-kreislauf-erkrankungen bei hyperglykämischen patienten
WO2002026193A3 (en) Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
NZ514691A (en) Method to type prion proteins
DE60222669D1 (de) Asthma-assoziiertes gen
EP1293570A3 (de) Verwendung des Aprataxin Gens zur Diagnose und Behandlung der früheinsetzenden Hinterstrangataxie (EAOH - early-onset spinocerebellar ataxia)
WO2001016158A3 (en) Bridging integrator-2 (bin2) nucleic acid molecules and proteins and uses therefor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties